Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG & ASHG Presidents’ Sign-on Letter to Congress Concerning Patent Eligibility Reform
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Board Statement Regarding 2018 ACMG Annual Meeting to Be Held in Charlotte, NC and Discriminatory Legislation
-
ACMG Efforts Lead AMA Resolution 122 to Support Coverage of Medical Food Products
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Letter to Congress Supporting the Accurate Education for Prenatal Screenings Act (HR 3441)
-
Joint Comments to CMS Concerning MolDx Program, Medicare Coverage, and Impact on MoPath Gapfill Determinations
-
ACMG Letter to Palmetto GBA Requesting Reconsideration of Cytogenetic Microarray Coverage